Overview

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Status:
Active, not recruiting

Trial end date:
2022-01-28

Target enrollment:

Participant gender:

Summary

This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in subjects with T2DM with peripheral neuropathy.

Phase:

Phase 2

Details

Lead Sponsor:

WinSanTor, Inc

Treatments:

Pirenzepine